Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 25 October, 2007

XTL Biopharm Ltd

XTL Announces $9.6 Mil Prvt Placement to Inst. ...


   XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to     
                            Institutional Investors                            

Valley Cottage, New York, October 25, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) today announced that it has entered into
definitive agreements with institutional investors relating to a private
placement of an aggregate of $9.6 million in gross proceeds of ordinary shares,
represented by American Depositary Receipts (ADRs). The lead investors in the
transaction are Perceptive Life Sciences Fund, Quogue Capital LLC, SCO Capital
Partners and Versant Capital.

Ron Bentsur, Chief Executive Officer of XTL, commented, "We are very pleased to
have consummated this financing with high-quality investors in the
biotechnology sector in the U.S. Following this offering, we believe that we
will have sufficient capital to execute our business plan and, more
importantly, to reach what we believe could be a major value-enhancing
milestone - the completion of our on-going randomized, placebo-controlled Phase
IIb trial of Bicifadine in diabetic neuropathic pain."

Pursuant to the securities purchase agreements, the Company will, following the
closing, issue approximately 7.1 million ADRs, representing approximately 71
million ordinary shares. No warrants were issued in the transaction. XTL has
agreed to register the ordinary shares and list the ADRs for trading on the
Nasdaq Stock Market.

Closing of the transaction is conditional upon, among other things, the
delisting of the Company's ordinary shares from the Official List of the United
Kingdom Listing Authority, scheduled to take place at 8:00 am (London Time) on
October 31, 2007.

Punk, Ziegel & Company, L.P. and Brean Murray, Carret & Co., LLC acted as
placement agents in the transaction.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain. XTL is also developing several
novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an
active in-licensing and acquisition program designed to identify and acquire
additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

The offering was made only to accredited investors, as such term is defined in
accordance with the Securities Act of 1933, as amended. The ordinary shares
have not been registered under the Securities Act of 1933, or any state
securities laws. Therefore, they may not be offered or sold in the United
States absent registration under or exemption from the Securities Act of 1933
and any applicable state securities laws. This announcement is neither an offer
to sell nor a solicitation of an offer to buy our ordinary shares or warrants
to purchase ordinary shares.

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225

Cautionary Statement

Some of the statements included in this press release, particularly those
anticipating future financial performance, the delisting of our ordinary shares
from the Official List of the United Kingdom Listing Authority, the clinical
and business prospects for our clinical compound Bicifadine, growth and
operating strategies and similar matters, may be forward-looking statements
that involve a number of risks and uncertainties. For those statements, we
claim the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995. Risk factors
that could adversely affect our operations are identified from time to time in
our reports filed with the Securities and Exchange Commission and the London
Stock Exchange, including our annual report on Form 20-F filed with the
Securities and Exchange Commission on March 23, 2007. Any forward-looking
statements set forth in this press release speak only as of the date of this
press release. We do not intend to update any of these forward-looking
statements to reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available at http://www.xtlbio.com.
The information in our website is not incorporated by reference into this press
release and is included as an inactive textual reference only.

                                                                              2